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A B S T R A C T 
 
 
 
 
Introduction:  Acute coronary syndrome (ACS) is a major cause of morbidity and mortality worldwide. Current Australian clinical guidelines 
recommend all patients with ACS receive comprehensive secondary prevention services to address this burden. Optimal patient outcomes rely on 
the timely and effective implementation of proven therapies and for secondary prevention to be successful, pharmacological interventions must be 
combined with cardiovascular disease (CVD) risk factor identification and management. The ability to implement clinical guidelines is also reliant 
on available resources, yet many rural populations in Australia do not have access to structured secondary prevention services, and the level of 
support available to them in the form of unstructured services is unclear. Our aim was to examine the scope of secondary prevention in a 
‘significantly restricted’ rural region of South Australia that does not have access to structured secondary prevention services.  
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Methods:  A retrospective analysis of medical records was undertaken to identify documented evidence of assessment and intervention for 
medical, lifestyle and behavioural CVD risk factors in hospital and at follow up in general practice (GP) clinics. Eligible participants were patients 
admitted to hospital in the Riverland Region of South Australia with myocardial infarction over a 12 month period. Of 77 eligible participants, 
permission was received to access the medical records of 55 patients in the hospital setting, and 34 of these 55 patients in GP clinic follow up.  
Results:  Most patients received baseline assessment for previous AMI (98%), history of hypertension (82%), history of diabetes (78%), and 
smoking status (76%). Most poorly documented was history of dyslipidaemia (53%) and obesity/ overweight (2%). Prescribing rates for 
recommended ACS medications at the time of hospital discharge were aspirin (90%), beta blockers (55%), ACE inhibitors (42%), lipid lowering 
medication (66%) and clopidogrel (64%). Overall prescribing rates in the 12 month study period rose to 80% or higher for all recommended 
medications. There was no evidence of interventions for smoking and obesity/ overweight in the hospital setting and 45% of smokers in the GP 
clinic setting received quit advice. Measurement of biomedical risk factors (blood lipid analysis and blood glucose levels) was suboptimal, and 
there was no evidence of a written action plan for chest pain for any participants. 
Conclusions:  Unstructured services provided some of the recommended elements of secondary prevention. However, deficits in care exist that 
have the potential to negatively impact patient outcomes in this already disadvantaged population. Future research needs to focus on the extent to 
which this and other rural and remote health care services are working within current clinical guidelines for the management of ACS, and 
subsequent patient outcomes. Urgent consideration must also be given to the introduction and evaluation of a more structured and consistent 
approach in this and other rural and remote regions of Australia. The development of rehabilitation and prevention services that build on existing 
strengths and resources have the potential to widen access, enhance current services and ensure care is based on best practice guidelines. This in 
turn may reduce the burden of CVD and improve the overall health and quality of life for patients in rural and remote Australia. 
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Introduction 
 
Acute coronary syndrome (ACS) includes a range of cardiac 
conditions including acute myocardial infarction (AMI) and angina1. 
Acute coronary syndrome is a major cause of morbidity and 
mortality and represents one of the most common causes of acute 
medical admissions in Australia2. Current Australian clinical 
guidelines1 recommend all patients with ACS should receive 
secondary prevention services that aim to maximise physical, 
psychological and social functioning, and enable people with ACS to 
lead fulfilling and productive lives2. 
 
A comprehensive approach to secondary prevention should include 
a combination of pharmacological interventions (eg antiplatelet 
agents, beta-blockers, angiotensin-converting enzyme inhibitors, 
lipid lowing medications and nitrates) and lifestyle and behavioural 
interventions. This approach has been shown to significantly reduce 
the risk of future cardiac events and deaths2-4, and leads to fewer re-
admissions to hospital, a shorter associated length of stay5-9, and 
enhanced medication management10. The National Heart 
Foundation Australia advocates a multidisciplinary approach to 
secondary prevention that includes nurses, doctors, physical 
therapists, dieticians, social workers and pharmacists working 
together to deliver therapeutic interventions and health behaviour 
advice for smoking cessation, physical inactivity, obesity, poor 
nutrition, high risk alcohol consumption, hypertension and 
dyslipidaemia2. In this case secondary prevention specifically aims to 
impact on cardiac risk factors and this differs from a primary 
prevention approach, which employs population health activities 
aimed at health promotion and disease prevention whereby it is 
more difficult to directly attribute impacts of primary healthcare 
activities and initiatives3. 
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Optimal patient outcomes rely on the timely and effective 
implementation of proven therapies11. Clinical guidelines for the 
management of ACS are readily available and are based on rigorous 
evidence11. However, the ability to implement these guidelines is 
dependent on the resources available in a particular region1,12. Rural 
and remote populations have a significantly higher incidence of 
cardiac mortality and morbidity than those in metropolitan areas2,13, 
yet they have poorer access to structured secondary prevention 
programs14,15 and are prescribed cardiovascular medications at half 
the rate of people living in major cities13.  
 
The Riverland region of South Australia is a 3 hour drive north east 
of state capital Adelaide with a population of just under 35 000 
people16. Cardiac related health services, including ad hoc 
secondary prevention, are provided by five hospitals and seven GP 
clinics in the region. In addition, patients have access to five visiting 
cardiologists who consult at the Riverland Regional Hospital’s Berri 
Campus and the Loxton District Hospital (three consult monthly 
and two consult bi-monthly). Patients are also required to travel to 
Adelaide for additional services, including admission to a 
metropolitan hospital for percutaneous coronary interventions and 
cardiac surgeries, and for cardiologist review if they are referred to 
specialist who does not consult in the Riverland17. 
 
With a Socio Economic Index for Areas rating (SEIFA) of 961, the 
Riverland Region is placed 0-5% below the non-metro average in 
terms of socio-economic disadvantage18. An 
Accessibility/Remoteness Index of Australia (ARIA) rating of 
3.6301–4.5262 classifies the Riverland as ‘moderately accessible’, 
or significantly restricted with regards to accessibility of goods, 
services and opportunities for social interaction16,18,19. This is 
significant due to the strong link between lower socioeconomic 
status and increased rates of cardiovascular disease (CVD) 
mortality18. The rate of CVD in the Riverland is well above the 
state average and is the primary killer in the region, accounting for 
nearly one-fifth of the total mortality burden16. Despite this high 
risk profile, there is currently no structured approach in the 
Riverland to secondary prevention, including cardiac rehabilitation, 
for patients with ACS. 
 
Much attention has been given in the literature to evaluating the 
scope, efficacy and adherence rates of structured secondary 
prevention services throughout Australia. However, we could find 
no evidence of studies reporting the scope and efficacy of 
unstructured secondary prevention services in rural Australia. 
Hence, the aim of this study was to examine initial assessment and 
ongoing secondary prevention of CVD risk factors for patients who 
have suffered AMI in a rural region of South Australia that does not 
offer structured secondary prevention services.  
 
 
Methods 
 
Study design and data collection tool 
 
A retrospective medical records analysis was undertaken to 
examine assessment of CVD risk factors and documented evidence 
of secondary prevention interventions within a 12 month time 
period. Medical record review has been used previously in 
Australia20,21, and internationally by the EUROASPIRE II study22 
and GRACE study23 to collect demographic and CVD risk factor 
data, and pharmacological interventions for CVD. The data 
abstraction tool, initially developed to evaluate an outpatient, 
hospital-based cardiac rehabilitation program in the USA24, was 
adapted for the current study to encompass current ‘Australian 
Clinical Guidelines for the Management of Acute Coronary 
Syndromes’1,4. Data were pooled prior to analysis to preserve 
health service and patient anonymity. 
 
 
Study participants and ethics approval 
 
All patients admitted to hospital in the Riverland region between 
1 July 2004 and 30 June 2005 with a primary diagnosis of AMI 
were eligible for inclusion in the study. Approval for the study was 
granted by the University of South Australia Human Research 
Ethics Committee.  
 
The current study was undertaken in two separate phases. 
 
Phase 1:  The aim of phase 1 was to examine baseline assessment of 
CVD risk factors and implementation of current clinical guidelines 
for secondary prevention of ACS in the hospital setting. Permission 
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to access medical records of eligible patients (n = 77) was sought 
from all five Riverland hospitals (Fig1). Three hospitals agreed 
(n = 48), and the internal ethics committees of the remaining two 
hospitals consented, providing the hospitals contacted eligible 
patients and obtained individual consent. The hospitals sent a 
written invitation to participate in the study to 29 patients, 7 of 
whom responded and consented (24% response rate). The medical 
records of 55 of a possible 77 (71%) patients were accessed in the 
hospital setting. 
 
Phase 2:  The aim of phase 2 was to examine follow-up care and 
the implementation of current clinical guidelines for secondary 
prevention of ACS in the GP clinic setting for the 55 patients in 
phase 1. All seven GP clinics in the region were approached for 
permission to access the medical records of those same 55 patients. 
Five GP clinics granted access to relevant medical records, one of 
which required the researcher to gain written consent from each 
patient. Two GP clinics did not allow access to medical records. A 
total of 34 of a possible 55 medical records were accessed in the GP 
clinic setting (Fig2). Of the 21 records not accessed; five patients 
attended GP clinics that declined participation in the study, 
two patients were not Riverland residents, five patients died prior 
to follow up, and nine patients did not provide written consent. 
 
Data collection 
 
Categories in the data collection tool were: demographics, 
prescribed medications, previous AMI, biomedical risk factors 
(diabetes, hypertension, dyslipidaemia), and lifestyle and 
behavioural risk factors (obesity or overweight, physical activity, 
independence with activities of daily living, dietary habits, alcohol 
consumption, smoking status, living arrangements and social 
support). 
 
Entries in the medical records were examined from the initial date 
of admission through to 12 months post-admission. Demographic 
and baseline CVD risk assessment data were collected in the 
hospital setting. Documented evidence of secondary prevention 
interventions, measurement of biomedical CVD risk factors, and 
deaths were collected in both the hospital and GP clinic setting, 
 
 
Statistical analysis 
 
Data were entered by hand on to the data abstraction tool and then 
entered into Microsoft Excel spreadsheets for analysis. Descriptive 
statistical analysis was used to calculate frequencies, mean values 
and range. Pharmacological and medical interventions in the 
current study refers to the assessment and measurement of 
biomedical risk factors, smoking and overweight/ obesity, referral 
to relevant health services, prescribing of recommended 
medications and the provision of a written action plan for chest 
pain.  
 
 
Results 
 
Demographic characteristics 
 
The mean age was 68.2 years (+/-15.5 SD), and 43 patients (78%) 
were male. Forty-five patients (82%) were born in Australia, and 
one patient (2%) was of Aboriginal or Torres Straight Islander 
decent. Demographic data is presented (Table 1). 
 
 
Baseline assessment of biomedical risk factors, 
smoking and obesity in the hospital setting 
 
The majority of patients were assessed for previous AMI and history 
of biomedical risk factors in the hospital setting, as depicted 
(Table 2). The most poorly documented risk factor was 
obesity/overweight, with only one patient (2%) diagnosed as obese 
(GP entry on admission form). While 22 patients (40%) were 
weighed during hospital admission, there was no evidence of body 
mass index (BMI) assessment or waist circumference measurement 
for any patient in the study. Also poorly documented was a history 
of dyslipidaemia with only 29 patients (53%) assessed in this 
category. 
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Figure 1: Phase One - hospital response rates and number of medical records accessed in the hospital setting. MR, Medical 
records. 
 
 
 
 
Figure 2: Phase 2 - GP clinic response rates and number of medical records accessed in GP clinic setting. F/U, Follow up; 
MR, medical records; Pt, patient. 
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Table 1: Demographic characteristics of patients (n = 55) assessed in the hospital setting 
 
Characteristic Yes  
n (%) 
No 
n (%) 
ND 
n (%) 
Mean age 68.2 (+/- 15.6 SD) – – 
Male 43 (78) 12 (22) 0 
Australian born 45 (82) 8 (15) 2 (3) 
ATSI decent 1 (2) 51 (93) 3 (5) 
English first language 16 (29) 3 (5) 36 (66) 
Past history of AMI 11 (20) 43 (78) 1 (2) 
               AMI, Acute myocardial infarction; ATSI, Aboriginal and/ or Torres Straight Islander decent; ND, not documented. 
 
 
 
Table 2:  Baseline assessment of biomedical and behavioural risk factors in the hospital setting (n = 55) 
 
Category Yes 
n (%) 
No 
n (%) 
ND 
n (%) 
Previous acute myocardial infarction 11 (20) 43 (78) 1 (2) 
History of hypertension 33 (60) 12 (22) 10 (18) 
History of dyslipidaemia 19 (35) 10 (18) 26 (47) 
History of diabetes 16 (29) 27 (49) 12 (22) 
Diagnosis obesity/ overweight 1 (2) 0 54 (98) 
Current smoker 16 (29) 26 (47) 13 (24) 
  ND, not documented. 
 
 
 
 
 
Pharmacological and medical interventions 
 
The proportion of patients referred to additional health services by 
hospitals and GP clinics was 89% and 62%, respectively. The most 
common referral in the hospital setting was to a metropolitan 
hospital (67%), and the most common referral in the GP clinic 
setting was for review by a cardiologist (62%). Six patients (11%) 
in the hospital setting and 10 patients (29%) in the GP clinic setting 
were not referred to any additional health services.  
 
There was no evidence of interventions for smoking or obesity/ 
overweight in the hospital setting. In the GP clinic setting, five of 
11 smokers (45%) received ‘quit’ advice and one smoker was 
prescribed nicotine replacement therapy. Sixteen of 34 patients 
(47%) followed up in the GP clinic setting had BMI assessed and 
11 patients were diagnosed as overweight/ obese. Two of these 
11 patients (18%) received weight loss advice. 
The majority of patients had their medication regimen altered in 
both the Riverland hospital setting (96%) and GP clinic setting 
(97%). During the 12 month study period, a high percentage of 
patients were prescribed medications recommended for all patients 
with ACS1,4 pS23. However, prescribing rates were as low as 42% for 
some recommended medications at the time of discharge from 
hospital (Table 3). 
 
Prescribing rates at the time of hospital discharge in the current 
(Riverland) study were compared with 9 Australian and 
international studies (Table 4). Riverland prescribing rates for 
aspirin were similar to other studies. However, Riverland 
prescribing rate for beta blockers and ACE inhibitors were lower 
than most of the comparison studies. Prescribing rates for lipid 
lowering drugs varied widely between the comparison studies, with 
the Riverland having the sixth lowest rate. 
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Table 3:  Recommended medications prescribed in the hospital setting (n = 55) and GP clinic setting (n = 34) during the 
12 month study period 
 
Medication Medication 
prescribed in 
hospital 
% 
Medication 
prescribed in GP 
clinic 
% 
Medication not 
prescribed 
% 
No F/U in GP Clinic 
(no consent/ death) 
% 
Prescribed medication 
during study  
% 
Aspirin† 90 5 0 5 100 
Clopidogrel † 64 4 14 18 86 
Beta Blocker¶ 55 16 13 16 87 
ACE inhibitor¶ 42 18 20 20 80 
Statin† 66 20 4 10 96 
Nitrates† 53  20 20 80 
F/U, Follow up. 
†Recommended for all patients unless contraindicated; ¶recommended for most patients unless contraindicated. 
 
 
 
 
Table 4:  Prescribing rates of recommended medications post acute coronary syndrome at the time of hospital discharge in 
the current (Riverland) study compared with 9 Australian and international studies20,22,23,25-30 
 
Study  Location Recommended ACS medications prescribed at hospital discharge % 
  Aspirin or antiplatelet 
drug 
Clopidogrel Aspirin Beta Blocker ACE 
Inhibitor 
Lipid 
lowering 
drug 
Riverland  
2004 – 2005 
(n = 55) 
5 Rural hospitals 
Australia 
- 64 90 55 42 66 
Acacia  
2005 – 2006 
(n = 3402) 
39 Metro, regional & 
rural hospitals 
Australia 
- 82.7 94 81.9 82.4 92.9 
Brisbane 
2000 – 2001 
(n = 397) 
3 Metro hospitals 
Australia 
94 - - 84 73 82 
Queensland 
1997 – 1998 
(n = 391) 
1 Tertiary (T) & 2 
community (C) 
hospitals Australia 
- - C 91 
T 89 
C 69 
T 71 
C 84 
T 66 
C 40 
T 41 
Tasmania 
1998  
(n=71) 
1 Metro hospital 
Australia 
- - 90.3 49.3 59.2 40.9 
Symphony 
1997 – 1999  
(n = 648) 
37 Countries 
(Australia/ New 
Zealand stats 
displayed only) 
- - 91 75 33 44 
Euroaspire II  
1999 – 2000 
(n = 8181) 
47 Hospitals in 15 
European countries 
90 - - 66 38 43 
Grace 
2005 
(n = 26 413) 
113 Hospitals in 14 
countries 
- - 95 91 77 85 
Crusade 
2001 – 2003 
(n = 77 760) 
457 Hospitals in the 
United States 
- 53.5 89.7 83.4 60.6 79.7 
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Table 4 (cont’d) 
 
Study  Location Recommended ACS medications prescribed at hospital discharge % 
  Aspirin or 
antiplatelet 
drug 
Clopidogrel Aspirin Beta Blocker ACE 
Inhibitor 
Lipid 
lowering 
drug 
Dunedin 
2001 – 2002 
(n = 577) 
1 Hospital United 
Kingdom 
- - 98 80 55 70 
ACS, Acute coronary syndrome. 
Study citations: Riverland (current study), Acacia [25], Brisbane [26], Queensland [27], Tasmania [20], Symphony [28], Euroaspire ii [22], Grace [23], Crusade [29], Dunedin [30]. 
 
 
 
Discussion 
 
Results of the current study indicate prescribing rates for ACS at 
the time of hospital discharge are suboptimal. However, overall 
prescribing rates in the 12 month period post-ACS are 80% or 
higher, suggesting a good level of guideline knowledge relating to 
pharmacological interventions31. It is interesting to note the wide 
variation in hospital and GP clinic prescribing rates, despite the 
same GP usually overseeing patient care in both settings. Further 
investigation to determine the reason for this variation is 
warranted. Any intervention to increase the percentage of patients 
being prescribed recommended medications prior to discharge is 
likely to favorably affect patient outcomes32. For example, 96% of 
patients were prescribed lipid lowering medication during the 
12 month study period; however, only 66% were discharged from 
hospital on lipid medication. Increasing this prescribing rate could 
enhance patient outcomes, as intensive statin therapy initiated 
immediately after ACS has been shown to reduce recurrent 
cardiovascular events and mortality33, and to improve the likelihood 
of patient adherence34.  
 
Increasing the use of recommended drug therapies, however, will 
not in itself raise the standard of secondary prevention of CVD1,22. 
For secondary prevention to be successful, pharmacological 
interventions must be combined with the assessment of biomedical, 
and lifestyle and behavioural assessment and interventions to 
address identified risk factors1,22. For example, blood lipid analysis 
is recommended for all patients with ACS34. In the current study 
only 29% of patients were tested in the hospital setting. This 
finding is lower than previously reported testing levels 
internationally of 39%35, 48%36 and 52.5%37. It is interesting to 
note that a considerably higher number of patients who were 
transferred to a tertiary hospital underwent lipid analysis when 
compared with patients discharged home (42% vs 20%). This 
difference may be explained by the lower mean age of patients 
transferred to tertiary care (62 vs 80.5 years), as advanced age has 
been associated with lower rates of lipid testing37. A significantly 
higher proportion of patients underwent lipid testing in the GP 
clinic setting (76%), again despite the same GP usually overseeing 
patient care from hospital to GP clinic.  
 
Several other recommendations were poorly met, including tight 
glycaemic control in patients with diabetes, screening all patients 
for type 2 diabetes, and assessment and interventions for smoking 
and obesity/overweight. In addition, no patients were provided 
with the recommended written action plan for chest pain1 which 
includes explanations about rest, administration of recommended 
medications and calling for assistance. These care deficits may 
indicate the level of knowledge of clinical guidelines31, or a lower 
importance placed on these interventions in comparison with other 
treatments38. Often, when patients with chronic illness are 
admitted to an acute care setting, medical attention is focused on 
treating the acute problem rather than discharge planning and long-
term care37,39. Time constraints and inadequate staffing levels have 
also been cited as reasons for suboptimal assessment and 
intervention for biomedical risk factors38. A combination of some 
or all of these factors may have led to the deficits identified in the 
current study. We would also argue that the absence of a structured 
approach to CR in the region contributed to these results. 
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Study limitations 
 
The retrospective nature of this study relies on the accuracy and 
completeness of original documentation. Documentation of risk 
factor assessment and measurement in the current study was 
incomplete, and the possibility that interventions were offered but 
not documented must be considered when interpreting the 
findings. The use of non-probability sampling and the small sample 
size limits generalisability to the wider population. However, the 
findings have potential relevance to other rural areas with similar 
populations. It is important to note that this study did not examine 
the appropriateness of medication class, dosage or adherence rates 
and, therefore, no determination can be made regarding this. It also 
important to note that pharmacological interventions were assessed 
for a period of 12 months post AMI, and no determination can be 
made regarding long-term prescribing rates. 
 
Conclusions 
 
Unstructured secondary prevention interventions are currently 
provided to many rural and remote communities in the absence of a 
structured program. However the unstructured nature of these 
services means there is variability in the implementation of services 
and evaluation of outcomes. Consequently the efficacy of 
unstructured CR and subsequent patient outcomes is also variable. 
The results of this study provide a valuable insight into the level of 
unstructured secondary prevention provided by rural health 
services in the absence of a formal program. Our findings 
demonstrate that unstructured secondary prevention services can 
provide some of the recommended elements. Nevertheless, we 
identified several deficits in care that have the potential to 
negatively impact patient outcomes in this already disadvantaged 
population. Future research needs to focus on the extent to which 
rural and remote health care services are working within current 
clinical guidelines for the management of ACS, the appropriateness 
of prescribed medications, long-term prescribing rates, and 
subsequent patient outcomes.  
 
There is strong evidence to support the efficacy of secondary 
prevention programs in relation to CVD related morbidity and 
mortality. In addition, secondary prevention is likely to be most 
beneficial in rural and remote settings where usual care may be less 
than optimal14,40. Urgent consideration must, therefore, be given to 
the introduction and evaluation of a more structured and systematic 
approach in this and other rural and remote regions of Australia. 
The development of rehabilitation and prevention services that 
build on existing strengths and resources have the potential to 
widen access, enhance current services and ensure care is based on 
best practice guidelines. This, in turn, may reduce the burden of 
CVD and improve the overall health and quality of life for patients 
in rural and remote Australia. 
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